Franz Hefti, co-director of the Lilly Institute for Genetic Medicine and CEO of Lilly sub Prevail

Lil­ly breaks the bank on the po­ten­tial for RNA with $700M in­vest­ment in Boston's Sea­port

In the lat­est boom across drug R&D, Big Phar­ma has dumped bil­lions in­to re­search for RNA-based ther­a­pies, bet­ting big on the fu­ture in that space. Now, Eli Lil­ly wants an even big­ger piece of the ac­tion and will plant its flag in Boston to help pave the way.

Lil­ly will dole out $700 mil­lion for a new re­search site at Boston’s Sea­port dis­trict as part of the com­pa­ny’s broad­er push in­to RNA med­i­cines, the In­di­anapo­lis-based drug­mak­er said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA